Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiovascular

Set Alert for Cardiovascular

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after the lecanemab results; Leqvio’s importance to Novartis; Pfizer’s secret sauce for digitalization; and Amgen’s clinical trial diversity efforts.

Clinical Trials Neurology

AstraZeneca Pulls Plug On Ionis’ PCSK9 Candidate

While the Phase IIb SOLANO trial of ION449 met its primary endpoint, AstraZeneca had set a high bar of 70% LDL cholesterol reduction for competitiveness that the study did not hit.

Clinical Trials Business Strategies

Leqvio Launch Will Be Fundamental To Success Of New Novartis

Discussion of the launch trajectory for the twice-yearly cholesterol therapy dominated the marketing portion of Novartis’s investor event and the firm is confident the foundations have been laid to push strong sales growth by the second half of next year.

Cardiovascular Launches

New Pure Play Novartis Vows To Up Its Game – With Help From In-House Challenger Ronny Gal

Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.

Companies Research & Development

Novo Nordisk Committed To Advancing In Cardiovascular

The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.

Cardiovascular Business Strategies

Alnylam’s Patisiran ATTR-CM Opportunity Boosted By New APOLLO-B Data

Phase III results for Onpattro (patisiran) in ATTR cardiomyopathy pave a path to approval – though the competitive profile is in question – and foreshadow potential success for follow-on drug vutrisiran.

Clinical Trials Strategy

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: new data for Factor XIa inhibitors; Farxiga in heart failure; Lumakras succeeds in lung cancer; MSD’s India head on company plans; and BeiGene’s confidence in IO/IO combinations.

Clinical Trials Research & Development

Novartis Changing Of The Guard Continues As R&D Chief Bradner Exits

A smooth handover hints at an amicable departure for Jay Bradner, but also gives CEO Vas Narasimhan the chance to refresh strategy with a new team.

Immune Disorders Cancer

Confidence In Factor XIa Inhibition Wavers After Bristol/Janssen And Bayer Data

BMS/Janssen’s milvexian and Bayer’s asundexian prevented strokes without major increases in severe bleeding and no fatal bleeds but Phase III outcomes are uncertain based on mixed Phase II data.

Clinical Trials Cardiovascular

Farxiga Matches Jardiance And Cements SGLT2 Benefits In Heart Failure

Treatment with Farxiga led to an 18% reduction in a composite endpoint comprising cardiovascular death or worsening heart failure, putting it in the same ballpark as Boehringer Ingelheim and Eli Lilly's Jardiance and its 21% reduction shown in the EMPEROR-Preserved trial last year.

Cardiovascular Clinical Trials

BMS/Janssen Will Begin Phase III For Factor XIa Inhibitor Milvexian By Year-End

Bristol and Janssen reported Phase II data at the ESC Congress in secondary stroke prevention, an indication not covered by Factor Xa inhibitors. BMS unveiled a three-indication Phase III program.

Cardiovascular Clinical Trials

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.

Commercial Deals
See All
UsernamePublicRestriction

Register